AstraZeneca is readying its own cancer-targeting drug for regulatory approval after trial win Oct 26, 2026 · Cris Tolomia Sone-Ve cut the risk of death by 42% in a Phase III gastric cancer trial; median survival was 10.6 months versus 6.4 Read more »